載入...
Development and 10-year history of a biosimilar: the example of Binocrit(®)
Patent expirations for several biological products have prompted the development of alternative versions, termed ‘biosimilars’, which have comparable quality, safety and efficacy to a licensed biological medicine (also referred to as the ‘reference’ medicine). The first biosimilars developed in onco...
Na minha lista:
| 發表在: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5912267/ https://ncbi.nlm.nih.gov/pubmed/29707043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918768419 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|